RBC Capital Maintains Outperform on Jazz Pharmaceuticals, Raises Price Target to $179
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Gregory Renza has maintained an 'Outperform' rating on Jazz Pharmaceuticals and raised the price target from $175 to $179.
October 23, 2024 | 7:10 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
RBC Capital has reaffirmed its 'Outperform' rating for Jazz Pharmaceuticals and increased the price target to $179, indicating positive expectations for the stock.
The increase in price target from $175 to $179 by RBC Capital suggests a positive outlook for Jazz Pharmaceuticals. The 'Outperform' rating indicates that the analyst expects the stock to perform better than the market average, which could lead to a short-term increase in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100